title: Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.
abstract: Benzodiazepines are commonly prescribed psycho-pharmaceuticals (e.g., for anxiety, tension, and insomnia); they are generally considered safe but have potential adverse effects. Benzodiazepine use in Canada versus internationally is comparably high, yet no recent comprehensive review of use, misuse, or related (e.g., morbidity, mortality) harm at the population level exists; the present review aimed to fill this gap. We searched four key scientific literature databases (Medline, CINAHL, EBM Reviews, and Web of Science) with relevant search terms, and collected relevant "gray literature" (e.g., survey, monitoring, government reports) data published in 1995-2015. Two reviewers conducted data screening and extraction; results were categorized and narratively summarized by key sub-topics. Levels of benzodiazepine use in the general population have been relatively stable in recent years; medical use is generally highest among older adults. Rates of non-medical use are fairly low in general but higher in marginalized (e.g., street drug use) populations; high and/or inappropriate prescribing appears common in older adults. Benzodiazepines are associated with various morbidity outcomes (e.g., accidents/injuries, cognitive decline, sleep disturbances, or psychiatric issues), again commonly observed in older adults; moreover, benzodiazepines are identified as a contributing factor in suicides and poisoning deaths. Overall there is a substantial benzodiazepine-related health problem burden-although lower than that for other psycho-medications (e.g., opioids)-in Canada, mainly as a result of overuse and/or morbidity. National benzodiazepine prescription guidelines are lacking, and few evaluated interventions to reduce benzodiazepine-related problems exist. There is a clear need for reducing inappropriate benzodiazepine use and related harm in Canada through improved evidence-based practice as well as monitoring and control.
authors.affiliation: Social and Epidemiological Research, Centre for Addiction and Mental Health (CAMH), 33 Russell St., Toronto, ON, M5S 2S1, Canada.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Murphy
authors.affiliation: Faculty of Health Sciences, Centre for Applied Research in Mental Health and Addictions (CARMHA), Simon Fraser University, Vancouver, BC, V6B 5K3, Canada.
authors.forename: Emily
authors.initials: E
authors.lastname: Wilson
authors.affiliation: Faculty of Health Sciences, Centre for Applied Research in Mental Health and Addictions (CARMHA), Simon Fraser University, Vancouver, BC, V6B 5K3, Canada.
authors.forename: Elliot M
authors.initials: EM
authors.lastname: Goldner
authors.affiliation: Social and Epidemiological Research, Centre for Addiction and Mental Health (CAMH), 33 Russell St., Toronto, ON, M5S 2S1, Canada. benedikt.fischer@utoronto.ca.|Department of Psychiatry, University of Toronto, Toronto, ON, M5T 1R8, Canada. benedikt.fischer@utoronto.ca.|Institute of Medical Science, University of Toronto, Toronto, ON, M5S 1A8, Canada. benedikt.fischer@utoronto.ca.
authors.forename: Benedikt
authors.initials: B
authors.lastname: Fischer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use*; D002170:Canada / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D011153:Population; D019966:Substance-Related Disorders / Q000453:epidemiology*
chemical_list: D001569:Benzodiazepines